Singapore, Oct. 29 -- NeuroRx, Inc, on 29 October 2019, announced that it has signed an agreement with GEM Global Yield LLC SCS ("GEM"), the New York-based private alternative investment group to provide the NeuroRx with up to HK$ 750 million over a 30-month term following a public listing of NeuroRx's common stock.

NeuroRx will use the funds to complete its phase 3 clinical trials and GMP manufacturing requirements in both the US and China for NRX-101, an FDA-designated Breakthrough Therapy in development for suicidal bipolar depression. The company further plans to initiate phase 2 clinical trials in the treatment of Suicidal Post-traumatic Stress Disorder (PTSD) under its Cooperative Research and Development Agreement with the US Depa...